Norgine: Remodeling, Not New Studies, Can Save Targaxan In The U.K.
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s NICE wants more data on quality of life, mortality benefit and cost-effectiveness before it can consider giving the green light to Norgine’s Targaxan (rifaxamin-a) for hepatic encephalopathy.